Type 2 inflammation influences the severity of post-acute sequelae of SARS-CoV-2, highlighting the need for targeted interventions. Innovative therapies like ALIS, tezepelumab, and dupilumab show ...
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today released its FY2024 Sustainability Report, for the period ending March 31, 2024. This report, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results